Enhancing shareholder value through exceptional business performance and practices, and through responsible and effective communication with its shareholders.
Adam Friedman, MD, FAAD and Professor and Chair of Dermatology at George Washington School of Medicine and Health Sciences, who has worked on the development of this novel therapeutic, will provide an overview on the burden of cutaneous lupus, the gap in care for diagnosed patients, and how HT-005 Z-Pods™ is designed to address both treatment and quality of life concerns for CLE patients. Dr. Friedman will also provide a brief overview of the proof-of-concept efficacy data from an animal study.
Register in advance for this meeting:
After registering, you will receive a confirmation email containing information about joining the meeting.